Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LT
Lantern Pharma Inc. Common Stock
LTRN
Volume
256.39K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LT
LTRN
LT
Lantern Pharma Inc. Common Stock
LTRN
News
·
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
Mkt Cap
$10.0M
Volume
256.38K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
Lantern Pharma, an AI-driven biotech company, is using machine learning and computational biology to accelerate cancer drug discovery, with three ongoing clinical trials targeting challenging and rare cancers.
GlobeNewswire Inc. · Sep 10, 2025
Lantern Pharma Narrows Loss in Q2
Lantern Pharma, an AI-driven oncology biotech, reported improved Q2 2025 financial results with narrowed GAAP losses and promising clinical trial progress across multiple drug candidates, particularly in cancer treatments.
The Motley Fool · Aug 13, 2025
32BJ Health Fund Selects Lantern as Surgery Network Partner
Lantern, a specialty care platform, announced a new partnership with the 32BJ Health Fund to provide access to high-quality surgeons and specialists at little to no cost for the union's members. This partnership aims to ensure affordable and accessible healthcare for the essential workforce represented by SEIU 32BJ.
GlobeNewswire Inc. · Nov 14, 2024
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, and enable the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.
GlobeNewswire Inc. · Oct 29, 2024
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from Benzinga Pro. United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer. United Natural Foods shares dipped 15.2% to $12.61 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line. Aptorum Group Limited (NASDAQ: APM) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business. NKGen Biotech, Inc. (NASDAQ: NKGN) gained 46.5% to $1.35. TRxADE HEALTH, Inc. (NASDAQ: MEDS) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share. Airship AI Holdings, Inc. (NASDAQ: AISP) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Enviva Inc. (NYSE: EVA) rose 33% to $0.9854 after gaining 42% on Tuesday. American Public Education, Inc. (NASDAQ: APEI) gained 31.8% to $14.99 following upbeat quarterly results. Dada Nexus Limited (NASDAQ: DADA) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements. Cemtrex, Inc. (NASDAQ: CETX) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature. Wave Life Sciences Ltd. (NYSE: WVE) gained 28.5% to $6.16 following upbeat quarterly results. Vincerx Pharma, Inc. (NASDAQ: VINC) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024. XORTX Therapeutics Inc. (NASDAQ: XRTX) rose 24.2% to $5.85. CareMax, Inc. (NASDAQ: CMAX) gained 23.8% to ...
Benzinga · Mar 6, 2024
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. Shares of Box, Inc. (NYSE: BOX) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter EPS and announced a $100 million expansion of its stock repurchase program. Total revenues were up 2% on a year-over-year basis. Billings were up 6% in the fourth quarter, coming in at $379.3 million. The company also issued first-quarter revenue guidance above estimates. Box shares climbed 7.3% to $29.25 on Wednesday. Here are some other big stocks recording gains in today’s session. TRxADE HEALTH, Inc. (NASDAQ: MEDS) shares jumped 39.2% to $11.19 after the company announced a special cash dividend of $8 per share. American Public Education, Inc. (NASDAQ: APEI) rose 31.8% to $14.99 following upbeat quarterly results. Dada Nexus Limited (NASDAQ: DADA) jumped 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements. Wave Life Sciences Ltd. (NYSE: WVE) rose 28.5% to $6.16 following upbeat quarterly results. CareMax, Inc. (NASDAQ: CMAX) jumped 23.8% to $14.72. Lantern Pharma Inc. (NASDAQ:
Benzinga · Mar 6, 2024
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Upgrades According to CIBC, the prior rating for BlackBerry Ltd (NYSE:BB) was changed from Underperformer to Neutral. In the fourth quarter, BlackBerry showed an EPS of $0.02, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $7.20 and a 52-week-low of $3.17. At the end of the last trading period, BlackBerry closed at $5.38. Evercore ISI Group upgraded the previous rating for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) from In-Line to Outperform. In the first quarter, Teva Pharmaceutical Indus showed an EPS of $0.40, compared to $0.55 from the year-ago quarter. The current stock performance of Teva Pharmaceutical Indus shows a 52-week-high of $11.45 and a 52-week-low of $6.78. Moreover, at the end of the last trading period, the closing price was at $8.13. According to B of A Securities, the prior rating for Cincinnati Financial Corp (NASDAQ:CINF) was changed from Neutral to Buy. Cincinnati Financial earned $0.89 in the first quarter, compared to $1.58 in the year-ago quarter. The current stock performance of Cincinnati Financial shows a 52-week-high of $130.66 and a 52-week-low of $88.67. Moreover, at the end of the last trading period, the closing price was at $102.69. According to UBS, the prior rating for Albemarle Corp (NYSE:ALB) was changed from Neutral to Buy. For the first quarter, Albemarle had an EPS of $10.32, compared to year-ago quarter EPS of $2.38. At the moment, the stock has a 52-week-high of $334.20 and a 52-week-low of $171.82. Albemarle closed at $207.99 at the end of the last trading period. BTIG upgraded the previous rating for Dynatrace Inc (NYSE:DT) from Neutral to Buy. Dynatrace earned $0.31 in the fourth quarter, compared to $0.17 in the year-ago quarter. The stock has a 52-week-high of $48.00 and a 52-week-low of $31.55. At the end of the last trading period, Dynatrace closed at $47.07. According to Mizuho, the prior rating for WEC Energy Group Inc (NYSE:WEC) was changed from Neutral to Buy. WEC Energy Group earned $1.61 in the first quarter, compared to $1.79 in the year-ago quarter. At the moment, the stock has a 52-week-high of $108.39 and a 52-week-low of $80.91. WEC Energy Group closed at $89.27 at the end of the last trading period. For Rambus Inc (NASDAQ:RMBS), Jefferies upgraded the previous rating of Hold to Buy. Rambus earned $0.03 in the first quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $54.23 and a 52-week-low of $20.00. Rambus closed at $53.55 at the end of the last trading period. According to Citigroup, the prior rating for Tencent Music Entertainment Group (NYSE:TME) was changed from Neutral to Buy. Tencent Music Enter Gr earned $0.13 in the first quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $9.29 and a 52-week-low of $3.15. At the end of the last trading period, Tencent Music Enter Gr closed at $8.31. Roth Capital upgraded the previous rating for Snap-on Inc (NYSE:SNA) from Neutral to Buy. Snap-on earned $4.60 in the first quarter, compared to $4.00 in the year-ago quarter. The stock has a 52-week-high of $265.02 and a 52-week-low of $190.37. At the end of the last trading period, Snap-on closed at $257.53. According to National Bank Financial Inc, the prior rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) was changed from Sector Perform to Outperform. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.57, compared to $0.46 from the year-ago quarter. At the moment, the stock has a 52-week-high of $72.68 and a 52-week-low of $48.75. Ritchie Bros Auctioneers closed at $51.85 at the end of the last trading period. See all analyst ratings upgrades. Downgrades For XP Inc (NASDAQ:XP), Banco Bradesco BBI S.A downgraded the previous rating of Outperform to Neutral. XP earned $0.28 in the first quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $25.18 and a 52-week-low of $10.30. ...Full story available on Benzinga.com
Benzinga · May 18, 2023
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announces that Panna Sharma, CEO and President, will present at the RHK Capital Disruptive Growth Conference in New York City.
GlobeNewswire Inc. · Dec 2, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $36.06 and a 52-week-low of $18.20. At the end of the last trading period, AnaptysBio closed at $28.85. According to Barclays, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Underweight to Equal-Weight. In the third quarter, First Solar showed an EPS of $0.46, compared to $0.42 from the year-ago quarter. At the moment, the stock has a 52-week-high of $148.20 and a 52-week-low of $59.60. First Solar closed at $145.57 at the end of the last trading period. According to Morgan Stanley, the prior rating for Gogo Inc (NASDAQ:GOGO) was changed from Underweight to Equal-Weight. For the second quarter, Gogo had an EPS of $0.17, compared to year-ago quarter EPS of $0.12. The stock has a 52-week-high of $23.69 and a 52-week-low of $11.57. At the end of the last trading period, Gogo closed at $14.22. RBC Capital upgraded the previous rating for Norfolk Southern Corp (NYSE:NSC) from Underperform to Sector Perform. Norfolk Southern earned $3.80 in the third quarter, compared to $3.06 in the year-ago quarter. The stock has a 52-week-high of $298.99 and a 52-week-low of $203.65. At the end of the last trading period, Norfolk Southern closed at $228.07. JP Morgan upgraded the previous rating for Lennox International Inc (NYSE:LII) from Underweight to Neutral. Lennox International earned $4.10 in the third quarter, compared to $3.40 in the year-ago quarter. The stock has a 52-week-high of $324.04 and a 52-week-low of $182.85. At the end of the last trading period, Lennox International closed at $233.57. JP Morgan upgraded the previous rating for Carvana Co (NYSE:CVNA) from Underweight to Neutral. Carvana earned $2.35 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $240.58 and a 52-week-low of $12.90. Carvana closed at $13.53 at the end of the last trading period. According to JP Morgan, the prior rating for Monster Beverage Corp (NASDAQ:MNST) was changed from Neutral to Overweight. For the second quarter, Monster Beverage had an EPS of $0.51, compared to year-ago quarter EPS of $0.75. The stock has a 52-week-high of $99.81 and a 52-week-low of $71.78. At the end of the last trading period, Monster Beverage closed at $93.72. See all analyst ratings upgrades. Downgrades For Abiomed Inc (NASDAQ:ABMD), Piper Sandler downgraded the previous rating of Overweight to Neutral. For the second quarter, Abiomed had an EPS of $1.30, compared to year-ago quarter EPS of $1.03. The current stock performance of Abiomed shows a 52-week-high of $368.97 and a 52-week-low of $219.84. Moreover, at the end of the last trading period, the closing price was at $252.08. For Varonis Systems Inc (NASDAQ:VRNS), Craig-Hallum downgraded the previous rating of Buy to Hold. Varonis Systems earned $0.05 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $51.60 and a 52-week-low of $22.92. At the end of the last trading period, Varonis Systems closed at $26.77. B of A Securities downgraded the previous rating for Inovio Pharmaceuticals Inc (NASDAQ:INO) from Neutral to Underperform. In the second quarter, Inovio Pharmaceuticals showed an EPS of $0.46, compared to $0.39 from the year-ago quarter. The current stock performance of Inovio Pharmaceuticals shows a 52-week-high of $5.27 and a 52-week-low of $1.38. Moreover, at the end of the last trading period, the closing price was at $2.16. According to Argus Research, the prior rating for Skechers USA Inc (NYSE:SKX) was changed from Buy to Hold. For the third quarter, Skechers USA had an EPS of $0.55, compared to year-ago quarter EPS of $0.66. At the moment, the stock has a 52-week-high of $49.89 and a 52-week-low of $31.28. Skechers USA closed at $34.43 at the end of the last trading period. Oppenheimer downgraded the previous rating for TuSimple Holdings Inc (NASDAQ:TSP) from Outperform to Perform. For the third quarter, TuSimple Hldgs had an EPS of $0.50, compared to year-ago quarter EPS of $0.54. The current stock performance of TuSimple Hldgs shows a 52-week-high of $37.24 and a 52-week-low of $3.21. Moreover, at the end of the last trading period, the closing price was at $3.43. For Ventas Inc (NYSE:VTR), Raymond James downgraded the previous rating of Strong Buy to Outperform. In the second quarter, Ventas showed an EPS of $0.72, compared to $0.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.02 and a 52-week-low of $35.33. Ventas closed at $39.13 at the end of the last trading period. For Steven Madden Ltd (NASDAQ:SHOO), Wedbush downgraded the previous rating of Outperform to Neutral. In the second quarter, Steven Madden showed an EPS of $0.63, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $49.84 and a 52-week-low of $26.36. At the end of the last trading period, Steven Madden closed at $29.87. According to Barclays, the prior rating for Principal Financial Group Inc (NASDAQ:PFG) was changed from Overweight to Equal-Weight. Principal Finl Gr earned $1.69 in the third quarter, compared to $1.69 in the year-ago quarter. The stock has a 52-week-high of $88.52 and a 52-week-low of $61.05. At the end of the last trading period, Principal Finl Gr closed at $88.13. Canaccord ...Full story available on Benzinga.com
Benzinga · Nov 1, 2022
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia Pharmaceuticals Inc (NASDAQ: ACAD) resubmitted supplemental marketing application for pimavanserin on June 17. The application seeks approval for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis. The target action date for the application is Aug. 4. Ipsen, Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer The European Commission has approved Ipsen SA's (OTC: IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval covers adult patients with locally advanced or metastatic DTC that is refractory or not eligible for radioactive iodine who have progressed during or after systemic therapy. This EC approval follows the FDA approval announced by Exelixis Inc (NASDAQ: EXEL) in September 2021 of Cabometyx for adult and pediatric patients with locally advanced or metastatic DTC. Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves Cortexyme Inc (NASDAQ: CRTX) has announced a further reduction to its headcount by 36%, bringing the total reduction to 67% from the January 2022 headcount levels. The majority of the employees will leave by the end of May 2022, and the remainder will leave by July 2022. In connection with this current reduction in force, the company estimates to incur approximately $700,000 in expenses. Sesen Bio Explores Strategic Alternatives Sesen Bio (NASDAQ: SESN) has initiated a ...
Benzinga · May 3, 2022
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
LT
LTRN
Lantern Pharma Inc. Common Stock
Buy
Sell
Market
Limit
Soon
LTRN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any LTRN yet.
Related Tickers
Earnings